>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

TGTX +20.6%, GNRC +6.6%, PERI +6.2%, PRO +5.9%, CZR +5.4%, GRBK +4.9%, DRVN +4.9%, TT +4.7%, AIZ +4.3%, CGAU +4.3%, FSLR +4.1%, TX +4%, DRH +4%, GRMN +3.5%, PSN +3.4%, EAT +3.2%, CMRE +3%, TM +2.7%, FRSH +2.6%, MTH +2.1%, FYBR +2.1%, SMG +1.8%, FWRG +1.7%, SUN +1.6%, BLKB +1.5%, DNB +1.5%, CHK +1.3% (also signs supply deal with Vitol), AEIS +1.2%, MTG +1%, AVA +1%, KHC +1%, PUMP +1%

Other news:

SLN +13.6% (topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran)
NVX +12% (finalizes $100 mln grant award from DOE)
CRSP +9.4% (completes FDA Advisory Committee Meeting for Exagamglogene Autotemcel for severe sickle cell disease)
GTE +4.6% (names new COO; also announces share repurchase plan reports earnings)
XPEV +3.6% (reports October deliveries)
GILT +2.2% (awarded ~$20 million in contract renewal and extension from Tier-1 MNO in the USA)
NVAX +2% (updated COVID-19 vaccine now approved in the EU)
DKNG +1.9% (to launch online sportsbook in Maine)
LI +1.8% (reports October deliveries)
SLI +1.5% (exercises option on South West Arkansas Project)
ARGX +1.2% (Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions)
MTTR +1% (issues response to "Sitzer/Burnett" verdict underscoring fundamental transformation of U.S. Real Estate Industry)

Analyst comments: